Table A3:
Number of Studies (Design) | Risk of Bias | Inconsistency | Indirectness | Imprecision | Publication Bias | Upgrade Considerations | Quality |
---|---|---|---|---|---|---|---|
Glucose variability | |||||||
1 (RCT, adults)32 | No serious limitations | Unknown | Serious limitations (−1)a | No serious limitations | Undetected | None | ⊕⊕⊕ Moderate |
Time in target glucose range (3.9–10.0 mmol/L [70–180 mg/dL]) in 24 hours | |||||||
1 (RCT, adults)32 | No serious limitations | Unknown | Serious limitations (−1)b | No serious limitations | Undetected | None | ⊕⊕⊕ Moderate |
Time above the target glucose range (> 13.3 mmol/L [70 mg/dL]) in 24 hours | |||||||
1 (RCT, adults)32 | No serious limitations | Unknown | Serious limitations (−1)b | No serious limitations | Undetected | None | ⊕⊕⊕ Moderate |
Time in hypoglycemia (< 3.9 mmol/L [70 mg/dL] within 24 hours) | |||||||
1 (RCT, adults)32 | Serious limitations (−1)c | Unknown | No serious limitations | No serious limitations | Undetected | None | ⊕⊕⊕ Moderate |
Time in hypoglycemia (< 3.9 mmol/L [70 mg/dL] at night [11 pm-6 am] within 7 hours) | |||||||
1 (RCT, adults)32 | Serious limitations (−1)c | Unknown | No serious limitations | No serious limitations | Undetected | None | ⊕⊕⊕ Moderate |
Hypoglycemia events (<3.9 mmol/L (70mg/dL) within 24 hours | |||||||
1 (RCT, adults)32 | No serious limitations | Unknown | Serious limitations (−1)b | No serious limitations | Undetected | None | ⊕⊕⊕ Moderate |
Quality of life | |||||||
1 (observational, adolescents)47,48 | Serious limitations (−1)d | Serious limitations (−1)f | No serious limitations | No serious limitations | Undetected | None | ⊕ Very low |
1 (RCT, adults)32 | Very serious limitations (−2)e | No serious limitations | No serious limitations | Undetected | None | ||
Fear of hypoglycemia | |||||||
1 (observational, adolescents)47 | Serious limitations (−1)g | No serious limitations | No serious limitations | No serious limitations | Undetected | None | ⊕⊕⊕ Moderatel |
1 (RCT, adults)32 | No serious limitations | Serious limitations (−1)h | No serious limitations | Undetected | None | ||
Glycated hemoglobin levels | |||||||
1 (RCT, adults)32 | No serious limitations | Serious limitations (−1)g | Very serious limitations (−2)i | No serious limitations | Undetected | None | ⊕ Very lowl |
2 (observational, adolescents, adults)47,50 | Serious limitations1)d | No serious limitations | Serious limitations1)j | Undetected | None | ||
Severe hypoglycemia events | |||||||
1 (observational, adults)50 | No serious limitations | Unknown | No serious limitations | Serious limitations (−1)k | Undetected | None | ⊕ Very lowl |
1 (RCT, adults)32 | No serious limitations | Serious limitations (−1)m | Very serious limitations (−2)k | Undetected | None | ||
Device-related adverse events | |||||||
1 (RCT, adults)32 | No serious limitations | Unknown | Serious limitations (−1)n | Very serious limitations (−2)k | Undetected | None | ⊕ Very low |
Abbreviations: GRADE, Grading of Recommendations Assessment, Development, and Evaluation; RCT, randomized controlled trial.
Results for standard deviation and coefficient of variation are reported as statistically significant, but standard deviation and coefficient of variation at the end of follow-up for both flash glucose monitoring and self-monitoring of blood glucose is larger than the maximum recommended clinical threshold.
Uncertainty if the difference is large enough to affect hard clinical outcomes.
Imputed data using the last observation carried forward.
Duration of self-monitoring of blood glucose in AI Hayek et al43 was not given. Potential for bias if effectiveness depends on duration of device use.
Only per-protocol results were shown. Unclear why intent-to-treat results were not reported or why some participants did not adhere to protocol.
Inconsistency in findings across all three studies.
Inconsistency in findings across studies.
Certain populations that are likely to fear hypoglycemia (e.g., those with hypoglycemia unawareness) were excluded.
Null glycated hemoglobin results were desirable, but we wanted to assess situations where null results are undesirable.
Large confidence intervals covering effect sizes that are consistent with null effects, favouring flash glucose monitoring, and favouring self-monitoring of blood glucose.
Very small number of events.
Conclusion on the certainty of evidence is based on the best quality study.
Certain populations that are likely to have severe hypoglycemia (e.g., those with hypoglycemia unawareness) were excluded.
A very small information size makes it difficult to generalize results beyond the sample in the study.